Innova Captab Announces Investor Presentation for Q3 FY26 Earnings Call
Innova Captab Limited will hold an investor presentation on January 27, 2026, to discuss Q3 and 9M FY26 results. The company reported a 42% YoY revenue growth in Q3 FY26 to ₹450.3 crore and a 23% YoY PAT growth to ₹42.1 crore. Exports contributed 35% to Q3 revenue. The company also received GMP compliance certificates from UK-MHRA and PIC/s.
The announcement pertains to an investor presentation and financial results discussion, which is a routine but important event for investors. While positive, it does not involve a major new strategic decision or a significant financial transaction that would warrant a 'High' impact.
The announcement highlights strong financial performance with significant year-on-year growth in revenue and profit, along with positive operational developments like GMP certifications, indicating a positive outlook.
Innova Captab Limited has announced an investor presentation for the analysts and institutional investor meeting to discuss the un-audited financial results for the quarter and nine months ended December 31, 2025. This follows their earlier intimation regarding an earnings call scheduled for January 27, 2026, at 12:00 Noon (IST).
The company has provided an investor presentation for the said earnings call, which was prepared based on reliable information. The presentation includes a company overview, highlighting its position as a leading pharmaceutical player with a comprehensive business model, serving over 300 CDMO customers globally and having a presence in 60+ countries.
Performance highlights for Q3 and 9M FY26 show a strong year-on-year revenue growth of 42% in Q3 and 27% in 9M FY26. This growth was driven by improved client engagement in the CDMO business and strategic geographic expansion in the branded generics vertical. Exports contributed 35% to the revenue mix in Q3 FY26. EBITDA saw a robust YoY growth of 40% in Q3 FY26, reaching ₹71.1 crore, and a 25% growth for 9M FY26, reaching ₹183.7 crore. Profit After Tax (PAT) for Q3 FY26 was ₹42.1 crore, a 23% YoY growth, and for 9M FY26, it was ₹102.8 crore, a 4% YoY growth.
The company also announced receiving Certificates of GMP Compliance from UK-MHRA for its Cephalosporin, Baddi unit, and from PIC/s (SMDC, Ukraine) for its Jammu facility. The Managing Director's commentary emphasized the strong performance, disciplined execution, and commitment to stakeholder value creation. The presentation also details historical financial performance, balance sheet information, and cash flow statements.
What to do with a filing like this
Innova Captab Limited filed this with the NSE as a statutory disclosure, categorised under other investor communications. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Innova Captab Limited. Read the original for the full detail.